Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In a paper published in Nature Neuroscience, the Fugger Group describe molecular pathways of MS neurodegeneration in unprecedented detail.

© Colin Behrens/Pixabay

Progressive multiple sclerosis (MS) is a common autoimmune disease characterised by neurodegeneration of the central nervous system. Despite progress in characterising the disease, MS is currently without effective treatments to tackle disease progression.

A new paper published in Nature Neuroscience provides a detailed picture of the molecular pathways altered in MS, tracking more than 4000 gene/protein pairings across stages of MS disease progression using spatial transcriptomics and proteomics.

Speaking to Nature Reviews Neurology, Professor Lars Fugger, leader of the Oxford Centre for Neuroinflammation at the MRC Human Immunology Unit  and lead author of the study said ‘'Spatial transcriptomics is a novel technique that can detect the expression of thousands of genes with spatial resolution directly in the tissue. Thus, it becomes possible to combine the structural detail of microscopy with high-dimensional measurements to capture complex disease pathways.'

By locating expression in the tissue and simultaneously measuring that gene expression, researchers were able to identify signals that could contribute to disease progression, and those that could represent potential therapeutic targets. By identifying protein and RNA expression changes in disease and highlighting those found in tissues affected in MS, the researchers created a prioritisation list for future drug targets.

Read the full paper online at Nature Neuroscience.

Similar stories

Biotech spinout MiroBio acquired by Gilead Sciences for ~£332m

Co-founded by Prof. Simon Davis, MiroBio focuses on developing therapeutics for inflammatory diseases.

New study shines light on the complex mechanisms of Fetal Growth Restriction in pregnancy

The paper, published in Nature Communications reveals key genes involved in the common developmental disease.

Seven research groups secure LEAF Sustainability Awards

The Laboratory Efficiency Assessment Framework (LEAF) aims to support research groups to embed sustainability into their work.

Playful science at Wheatley and Holton Play and Activity Day 2022

On Saturday 16th July, volunteers from the MRC WIMM talked the science of blood, lab techniques and coding at the Play and Activity Day organised by the Oxfordshire Play Association.

Gold LEAF Award for Kusumbe Lab

The award demonstrates the group's commitment to sustainable science.

Novel all-in-one vaccine developed to tackle future coronavirus threats

Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.